Exercising an option as part of a 2015 collaboration, Astellas Pharma has acquired Potenza Therapeutics in a deal worth potentially up to US$404.7 M. It gives Astellas access to three immuno-oncology therapies developed under the original agreement: Phase I assets PTZ-201, an immune checkpoint inhibitor, PTZ-329, a T-regulatory cell inhibitor, and PTZ-522, a GITR agonistic antibody that recently gained IND clearance from the US FDA.